Quarterly report pursuant to Section 13 or 15(d)

REVENUES - Disaggregated (Details)

v3.23.3
REVENUES - Disaggregated (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Total revenues $ 28,134 $ 22,410 $ 81,090 $ 68,964
Gross product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 38,585 26,977 105,239 76,022
Discounts and allowances        
Disaggregation of Revenue [Line Items]        
Total revenues (11,456) (7,789) (30,484) (22,087)
Product sales, net        
Disaggregation of Revenue [Line Items]        
Total revenues 27,129 19,188 74,755 53,935
License revenues        
Disaggregation of Revenue [Line Items]        
Total revenues       2,545
Development milestones        
Disaggregation of Revenue [Line Items]        
Total revenues 75   75 5,000
Royalty, delivery of drug supplies and others        
Disaggregation of Revenue [Line Items]        
Total revenues 930 722 5,260 4,984
Contract revenues from collaborations        
Disaggregation of Revenue [Line Items]        
Total revenues $ 1,005 722 5,335 12,529
Government contract        
Disaggregation of Revenue [Line Items]        
Total revenues   $ 2,500 $ 1,000 $ 2,500